Exact Sciences Q1 EPS Estimate Boosted by Leerink Partnrs

Exact Sciences Co. (NASDAQ:EXAS) – Equities researchers at Leerink Partnrs upped their Q1 2025 earnings estimates for shares of Exact Sciences in a research report issued to clients and investors on Thursday, February 20th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of ($0.06) for the quarter, up from their prior forecast of ($0.10). The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q2 2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.26 EPS and Q4 2026 earnings at $0.34 EPS.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. The business had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%.

A number of other brokerages have also issued reports on EXAS. Jefferies Financial Group raised their price objective on shares of Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Citigroup decreased their target price on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. BTIG Research increased their target price on shares of Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Craig Hallum decreased their target price on shares of Exact Sciences from $82.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, Robert W. Baird decreased their target price on shares of Exact Sciences from $70.00 to $67.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $72.24.

Exact Sciences Stock Down 2.1 %

Shares of NASDAQ EXAS opened at $50.18 on Monday. The company has a 50 day simple moving average of $54.52 and a 200 day simple moving average of $59.95. The firm has a market cap of $9.32 billion, a PE ratio of -9.01 and a beta of 1.24. Exact Sciences has a 1 year low of $40.62 and a 1 year high of $79.62. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93.

Institutional Trading of Exact Sciences

Large investors have recently modified their holdings of the stock. Huntington National Bank grew its position in Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 352 shares during the period. RPg Family Wealth Advisory LLC acquired a new stake in Exact Sciences in the 3rd quarter valued at $34,000. Capital Performance Advisors LLP acquired a new stake in Exact Sciences in the 3rd quarter valued at $35,000. Vestor Capital LLC acquired a new stake in Exact Sciences in the 3rd quarter valued at $46,000. Finally, Asset Planning Inc acquired a new stake in Exact Sciences in the 4th quarter valued at $40,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.